HN2011001446A - Compuesto utiles para inhibir chk1 - Google Patents

Compuesto utiles para inhibir chk1

Info

Publication number
HN2011001446A
HN2011001446A HN2011001446A HN2011001446A HN2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A
Authority
HN
Honduras
Prior art keywords
compound useful
inhibit chk1
chk1
inhibit
useful
Prior art date
Application number
HN2011001446A
Other languages
English (en)
Spanish (es)
Inventor
Farouz Francine
Kasar Ramesh
Coast Orth Holcomb Ryan
Scott Myers Steven
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001446A publication Critical patent/HN2011001446A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HN2011001446A 2008-12-17 2011-06-01 Compuesto utiles para inhibir chk1 HN2011001446A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17

Publications (1)

Publication Number Publication Date
HN2011001446A true HN2011001446A (es) 2013-08-05

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001446A HN2011001446A (es) 2008-12-17 2011-06-01 Compuesto utiles para inhibir chk1

Country Status (37)

Country Link
EP (1) EP2379532B1 (enExample)
JP (1) JP5705743B2 (enExample)
KR (1) KR101301777B1 (enExample)
CN (1) CN102245597B (enExample)
AR (1) AR074471A1 (enExample)
AU (1) AU2009333433B2 (enExample)
BR (1) BRPI0922468A2 (enExample)
CA (1) CA2746423C (enExample)
CL (1) CL2011001463A1 (enExample)
CO (1) CO6382122A2 (enExample)
CR (1) CR20110339A (enExample)
CY (1) CY1113930T1 (enExample)
DK (1) DK2379532T3 (enExample)
DO (1) DOP2011000185A (enExample)
EA (1) EA018118B1 (enExample)
EC (1) ECSP11011136A (enExample)
ES (1) ES2401558T3 (enExample)
HN (1) HN2011001446A (enExample)
HR (1) HRP20130167T1 (enExample)
IL (1) IL213160A (enExample)
JO (1) JO2886B1 (enExample)
MA (1) MA32901B1 (enExample)
MX (1) MX2011006603A (enExample)
MY (1) MY156998A (enExample)
NZ (1) NZ593440A (enExample)
PA (1) PA8850801A1 (enExample)
PE (1) PE20120077A1 (enExample)
PL (1) PL2379532T3 (enExample)
PT (1) PT2379532E (enExample)
RS (1) RS52739B (enExample)
SG (1) SG172222A1 (enExample)
SI (1) SI2379532T1 (enExample)
TN (1) TN2011000298A1 (enExample)
TW (1) TWI436996B (enExample)
UA (1) UA101998C2 (enExample)
WO (1) WO2010077758A1 (enExample)
ZA (1) ZA201103946B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
AR083575A1 (es) * 2010-11-08 2013-03-06 Lilly Co Eli Aminopirazoles para inhibir la proteinquinasa chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
AR106772A1 (es) * 2015-12-07 2018-02-14 Lilly Co Eli Sales de (s)-lactato
US20180228795A1 (en) * 2015-12-15 2018-08-16 Eli Lilly And Company Combination therapy for cancer
HRP20220351T1 (hr) 2016-02-04 2022-05-13 Pharmaengine, Inc. 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
MX2019011506A (es) 2017-03-31 2019-11-01 Seattle Genetics Inc Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US11634424B2 (en) 2019-11-29 2023-04-25 Medshine Discovery Inc. Diazaindole derivative and use thereof as CHK1 inhibitor
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
KR20230115988A (ko) 2020-11-30 2023-08-03 스미토모 파마 가부시키가이샤 5-헤테로아릴-1h-피라졸-3-아민 유도체
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
BR112023024571A2 (pt) 2021-05-27 2024-02-06 Boundless Bio Inc Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
JPWO2023120696A1 (enExample) 2021-12-24 2023-06-29
JPWO2023229032A1 (enExample) * 2022-05-27 2023-11-30
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
MXPA06000933A (es) * 2003-07-25 2006-03-30 Pfizer Compuestos de aminopirazol y uso como inhibidores de chk1.
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
IL213160A (en) 2013-12-31
CL2011001463A1 (es) 2012-01-20
CR20110339A (es) 2011-09-14
CO6382122A2 (es) 2012-02-15
CY1113930T1 (el) 2016-07-27
DOP2011000185A (es) 2017-12-15
HRP20130167T1 (hr) 2013-03-31
PA8850801A1 (es) 2010-07-27
MA32901B1 (fr) 2011-12-01
CN102245597A (zh) 2011-11-16
SG172222A1 (en) 2011-07-28
KR101301777B1 (ko) 2013-08-30
SI2379532T1 (sl) 2013-05-31
AR074471A1 (es) 2011-01-19
UA101998C2 (ru) 2013-05-27
DK2379532T3 (da) 2013-03-18
ES2401558T3 (es) 2013-04-22
PE20120077A1 (es) 2012-02-06
EP2379532A1 (en) 2011-10-26
CN102245597B (zh) 2014-04-16
IL213160A0 (en) 2011-07-31
JO2886B1 (en) 2015-03-15
TW201029994A (en) 2010-08-16
JP2012512249A (ja) 2012-05-31
AU2009333433A1 (en) 2011-06-30
ZA201103946B (en) 2012-10-31
CA2746423A1 (en) 2010-07-08
AU2009333433B2 (en) 2012-06-14
EP2379532B1 (en) 2013-02-20
CA2746423C (en) 2014-01-14
MX2011006603A (es) 2011-09-27
MY156998A (en) 2016-04-15
TWI436996B (zh) 2014-05-11
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
JP5705743B2 (ja) 2015-04-22
ECSP11011136A (es) 2011-07-29
EA201170834A1 (ru) 2011-12-30
EA018118B1 (ru) 2013-05-30
PT2379532E (pt) 2013-03-25
WO2010077758A1 (en) 2010-07-08
KR20110084539A (ko) 2011-07-25
PL2379532T3 (pl) 2013-07-31
RS52739B (sr) 2013-08-30
BRPI0922468A2 (pt) 2020-08-04
HK1160110A1 (en) 2012-08-10

Similar Documents

Publication Publication Date Title
HN2011001446A (es) Compuesto utiles para inhibir chk1
GT201200164A (es) "nuevos compuestos de espiropiperidina"
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BRPI0717125B8 (pt) Composto derivado de ftalazinona como forma cristalina a, métodos para obter o mesmo e usos terapêuticos do dito composto
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
UY32062A (es) Inhibidores de beta-secretasa
CR20110560A (es) Métodos de tratamiento para tumores sólidos
UY32045A (es) Compuesto amida
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
HN2008001374A (es) Compuestos de cinamida policiclicos
EA201071144A1 (ru) Гетероциклические производные
SV2011003855A (es) Heteroarilos sustituidos
EA201001639A1 (ru) Композиции и способы их получения и применения
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
GT201400111A (es) Triazolopiridinas sustituidas
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)